Radiopharmaceutical developer Navidea Biopharmaceuticals is claiming victories in several motions in a legal case pitting the company against its former CEO, Dr. Michael Goldberg.
Goldberg was CEO of Navidea from 2016 until August 2018, when he resigned and was replaced by Jed Latkin. Goldberg remained president and CEO of Navidea's majority-owned subsidiary Macrophage Therapeutics until he was removed from that capacity in February 2019 and replaced by Latkin.
Navidea subsequently filed a complaint against Goldberg in the U.S. District Court for the Southern District of New York, charging Goldberg with breach of contract. The company filed another complaint in a Delaware state court.
On December 30, Navidea claimed several victories in motions in the case. For example, the company cited favorable court rulings indicating that its actions in reconstituting Macrophage's board did not breach a previous agreement with Goldberg. The New York court also rejected Goldberg's counterclaim of wrongful termination as CEO of Macrophage.
